NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · Real-Time Price · USD
0.3165
-0.0229 (-6.75%)
At close: Sep 4, 2026, 4:00 PM EDT
0.3394
+0.0229 (7.24%)
After-hours: Sep 4, 2026, 6:15 PM EDT
NEXGEL Revenue
NEXGEL had revenue of $3.69M in the quarter ending June 30, 2026, with 27.81% growth. This brings the company's revenue in the last twelve months to $12.07M, up 3.38% year-over-year. In the year 2025, NEXGEL had annual revenue of $11.42M with 31.46% growth.
Revenue (ttm)
$12.07M
Revenue Growth
+3.38%
P/S Ratio
0.26
Revenue / Employee
$635,105
Employees
19
Market Cap
3.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.42M | 2.73M | 31.46% |
| Dec 31, 2024 | 8.69M | 4.60M | 112.47% |
| Dec 31, 2023 | 4.09M | 2.04M | 99.66% |
| Dec 31, 2022 | 2.05M | 497.00K | 32.04% |
| Dec 31, 2021 | 1.55M | 877.00K | 130.12% |
| Dec 31, 2020 | 674.00K | -43.00K | -6.00% |
| Dec 31, 2019 | 717.00K | -1.50M | -67.60% |
| Dec 31, 2018 | 2.21M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 87.81M |
| Retractable Technologies | 33.90M |
| Bionano Genomics | 30.18M |
| Precision Optics Corporation | 28.94M |
| Nephros | 20.72M |
| Milestone Scientific | 9.42M |
| Lucyd | 3.41M |
| Femasys | 2.30M |
NXGL News
- 13 days ago - NexGel downgraded to Hold from Buy at Maxim - TheFly
- 13 days ago - NexGel downgraded to Hold from Buy at Maxim - TheFly
- 13 days ago - NEXGEL Proxy statement: Proxy filing - Filings
- 17 days ago - NexGel CEO Adam Levy to depart, Brian Kieser appointed interim CEO - TheFly
- 17 days ago - NexGel announces strategic review - TheFly
- 17 days ago - NexGel registers to sell 15.25M shares of common stock for holders - TheFly
- 17 days ago - NEXGEL Registration statement: Registration filing - Filings
- 20 days ago - NEXGEL Quarterly report: Q2 2026 - Filings